{
    "clinical_study": {
        "@rank": "38624", 
        "arm_group": {
            "arm_group_label": "PET Imaging with [18F]MNI-659", 
            "arm_group_type": "Experimental", 
            "description": "All subjects (both HDGECs and HCs) will receive single intravenous doses of the radioligands [11C]raclopride (non-investigational medicinal product [NIMP]) and [18F]MNI-659 (investigational medicinal product [IMP]).\nThe radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.\nThe injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight \u00b1 10%.\nThe injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight \u00b1 10%."
        }, 
        "brief_summary": {
            "textblock": "The aim of this study is to measure the availability of the PDE10A enzyme in Huntington\n      disease gene expansion carriers (HDGECs) using the recently developed radioligand\n      [18F]MNI-659. The study will be cross-sectional, examining HDGECs at different stages of the\n      disease (pre-manifest, stage 1 and stage 2), in comparison with Healthy Controls (HCs). The\n      HDGECs included in this study will be recruited from the large database of the REGISTRY\n      study."
        }, 
        "brief_title": "[PETDE10] Imaging of PDE10A Enzyme Levels in Huntington's Disease Gene Expansion Carriers and Healthy Controls With PET.", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Huntington's Disease", 
        "condition_browse": {
            "mesh_term": "Huntington Disease"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Capacity to give full informed consent in writing, and have read and signed the\n             informed consent\n\n          -  Age 18 to 70 years, inclusive\n\n          -  HCs: Healthy according to medical history, physical examination, ECG, vital signs,\n             laboratory assessment and MRI, with a body mass index between 19 and 27 (both\n             inclusive)\n\n          -  HDGECs: Otherwise healthy according to medical history, no co-morbidity of psychotic\n             disorders, physical examination, vital signs and laboratory assessments\n\n          -  HDGECs:\n\n        (A) HD Stage 1 or HD Stage 2:  Patients with a clinical diagnosis of HD, defined by the\n        presence of noticeable motor disorder and 40  CAG  repeats (HD stage 1: Total Functional\n        Capacity (TFC) 11-13, HD stage 2: TFC 7-10); (B) Pre-manifest: Subjects that are carriers\n        of the mutant Huntingtin gene with \u226540 CAG repeats, a disease burden score \u2265 275\n        (calculated by the equation ((CAGn-35.5) X age)), and a Total Motor Score (TMS) \u2264 5.\n\n          -  Able and willing to travel to Stockholm\n\n          -  Willing to comply with use of adequate contraceptive measures:\n\n        Exclusion Criteria:\n\n          -  Any disease, condition or concomitant medications that significantly compromises the\n             function of the body systems and that, in the opinion of the Investigator might\n             interfere with the conduct of the study or the interpretation\n\n          -  Regular use of any medication prohibited by this protocol with the exception for\n             Viagra, Levitra and Cialis, which may be temporarily discontinued prior to the PET\n             measurements\n\n          -  HDGECs: History of other neurological condition (including brain surgery,\n             intracranial haematoma, stroke/cerebrovascular disorders, epilepsy), co-morbidity of\n             psychotic disorders\n\n          -  HCs: Anamnesis/medical history of neurological conditions (Alzheimer\u00b4s disease,\n             dementia, Parkinson\u00b4s disease, brain surgery, intracranial haematoma,\n             stroke/cerebrovascular disorders, epilepsy) or psychiatric conditions schizophrenia,\n             depression, bipolar disorder, attention-deficit hyperactivity disorder)\n\n          -  HCs: Family history of HD\n\n          -  History of or current alcohol or drug abuse or dependence\n\n          -  History of anaphylactoid or anaphylactic reactions to any allergen including drugs\n             and contrast media\n\n          -  Haematological or biochemical parameters that are outside the normal range and are\n             considered clinically significant by the Investigator\n\n          -  Clinical relevant findings in the 12-lead ECG as determined by the evaluating\n             physician\n\n          -  Donation of blood (450 mL) within three months prior to Visit 3\n\n          -  Contraindication to MRI, such as known claustrophobia, presence of metal devises or\n             implants (e.g. pacemaker, vascular- or heart- valves, stents, clips), metal deposited\n             in the body (e.g. bullets or shells), or metal grains in the eyes\n\n          -  Participating in a clinical trial within the past 3 months\n\n          -  HCs: previous participation in another PET study\n\n          -  Positive viral test result for Hepatitis B or C or HIV 1 or 2\n\n          -  Female subjects: breast-feeding or positive pregnancy test at screening or at Visit 3\n\n          -  Contraindication for arterial cannulation (by assessment of Allen's test)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02061722", 
            "org_study_id": "PET Study in HD and HC"
        }, 
        "intervention": {
            "arm_group_label": "PET Imaging with [18F]MNI-659", 
            "description": "The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.\nThe injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight \u00b1 10%.\nThe injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight \u00b1 10%.", 
            "intervention_name": "PET Imaging with [18F]MNI-659", 
            "intervention_type": "Radiation"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 11, 2014", 
        "location": [
            {
                "contact": {
                    "email": "jnielsen@sund.ku.dk", 
                    "last_name": "Jorgen Nielsen, MD, PI", 
                    "phone": "+45 35 45 68 01"
                }, 
                "facility": {
                    "address": {
                        "city": "Copenhagen", 
                        "country": "Denmark"
                    }, 
                    "name": "The Memory Clinic, Rigshopitalet"
                }, 
                "investigator": {
                    "last_name": "Jorgen Nielsen, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "v.roedig@lumc.nl", 
                    "last_name": "Verena Rodig, MSc", 
                    "phone": "+31 715266149"
                }, 
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "K5Q112"
                    }, 
                    "name": "Leiden University Medical Center, Department of Neurology"
                }, 
                "investigator": {
                    "last_name": "R.A.C. Roos, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "rwehus@ous-hf.no", 
                    "last_name": "Ragnhild Wehus", 
                    "phone": "+47 23 07 55 80"
                }, 
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "0372 Oslo"
                    }, 
                    "name": "University of Oslo, Nevrologisk poliklinikk"
                }, 
                "investigator": {
                    "last_name": "Jan Frich, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jan.reimer@med.lu.se", 
                    "last_name": "Jan Reimer, RN", 
                    "phone": "+46 46 17 41 23"
                }, 
                "facility": {
                    "address": {
                        "city": "Lund", 
                        "country": "Sweden", 
                        "zip": "SE-221 85"
                    }, 
                    "name": "Skane Universitetssjukhus Lund, Neurologiska kliniken"
                }, 
                "investigator": {
                    "last_name": "Hakan Widner, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tina.wallden-reza-soltani@karolinska.se", 
                    "last_name": "Tina Wallden, RN", 
                    "phone": "+46 70 627 41 40"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-141 86"
                    }, 
                    "name": "Karolinska Universitetssjukhus, Huddinge"
                }, 
                "investigator": [
                    {
                        "last_name": "Per Svenningsson, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Martin Paucar Arce, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "nina.knave@ki.se", 
                    "last_name": "Nina Knave, RN", 
                    "phone": "+46 8 517 728 85"
                }, 
                "contact_backup": {
                    "email": "karin.olsson.1@ki.se", 
                    "last_name": "Karin Olsson, RN", 
                    "phone": "'+46 8 517 744 22"
                }, 
                "facility": {
                    "address": {
                        "city": "Stockholm", 
                        "country": "Sweden", 
                        "zip": "SE-171 76"
                    }, 
                    "name": "Karolinska University Hospital"
                }, 
                "investigator": [
                    {
                        "last_name": "Andrea Varrone, MD, PhD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Patrik Fazio, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jimmy.sundblom@neuro.uu.se", 
                    "last_name": "Jimmy Sundblom, MD, PhD", 
                    "phone": "+46 18 611 00 00"
                }, 
                "facility": {
                    "address": {
                        "city": "Uppsala", 
                        "country": "Sweden", 
                        "zip": "SE-751 85"
                    }, 
                    "name": "Neurologkliniken Akademiska sjukhuset, ing 85"
                }, 
                "investigator": {
                    "last_name": "Jimmy Sundblom, MD, PhD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Denmark", 
                "Netherlands", 
                "Norway", 
                "Sweden"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "[PETDE10] Imaging of Phosphodiesterase 10 A (PDE10A) Enzyme Levels in the Living Human Brain of Huntington\u00b4s Disease Gene Expansion Carriers and Healthy Controls With Positron Emission Tomography", 
        "overall_official": [
            {
                "affiliation": "Ulm University Hospital", 
                "last_name": "Bernhard Landwehrmeyer, MD, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "CHDI Foundation, Inc.", 
                "last_name": "Cristina Sampaio, MD, PhD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Sweden: Medical Products Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary outcome measure will be the distribution volume (VT) in the striatum (caudate and putamen), globus pallidus, and ventral striatum estimated using kinetic and graphical analysis. Thalamus, cortex and cerebellum will also be examined.", 
            "safety_issue": "No", 
            "time_frame": "Visit 3:  For HD subjects, this will occur within 90 days from the Screening Visit.  For Healthy Controls, this will occur within 28 days of Screening visit."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02061722"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "CHDI Foundation, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "CHDI Foundation, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}